Novo Nordisk A/S (CPH:NOVO.B)
315.20
-0.10 (-0.03%)
Nov 4, 2025, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B
Revenue Growth
+20.90%
P/S Ratio
4.49
Revenue / Employee
3.98M
Employees
77,349
Market Cap
1.40T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.87B |
| H. Lundbeck | 23.52B |
| Genmab | 23.16B |
| Demant | 22.59B |
| GN Store Nord | 17.33B |
| Zealand Pharma | 9.11B |
| Bavarian Nordic | 6.46B |
| Ambu A/S | 5.96B |
Novo Nordisk News
- 23 minutes ago - Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount - CNBC
- 31 minutes ago - Novo Nordisk Q3 sales beat forecasts in new CEO's maiden quarter - Reuters
- 40 minutes ago - Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues - GlobeNewsWire
- 49 minutes ago - Europe to open lower as markets question tech valuations; Novo Nordisk earnings ahead - CNBC
- 6 hours ago - Pfizer and Novo Nordisk Intensify Bidding War for Metsera - GuruFocus
- 8 hours ago - Obesity drugs may get Medicare access under deal with White House: reports - MarketWatch
- 9 hours ago - Novo Nordisk Reports Earnings on Wednesday. What to Expect. - Barrons
- 9 hours ago - White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound - NBC News